Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 6/20 | 0.55 |
| ▸ | MMP13 | P45452 | 4/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4654958 | 0.84 | MAPT (0.47) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL4206102 | 0.83 | TSHR (0.53) | MMP12TSHRCTSGCTRB1CA12 | |
| SCHEMBL14338691 | 0.83 | TSHR (0.53) | MMP12TSHRCTSGCTRB1CA12 | |
| SCHEMBL7633821 | 0.83 | ABCB1 (0.57) | POLBTRPA1ALDH1A1 | |
| SCHEMBL7084641 | 0.82 | PTGER1 (0.47) | POLBGAAMEN1KMT2A | |
| SCHEMBL7084643 | 0.82 | PTGER1 (0.47) | POLBGAAMEN1KMT2A | |
| SCHEMBL8170975 | 0.82 | DPP4 (0.49) | MMP12DPP4TSHRCTSGCTRB1 | |
| SCHEMBL8170979 | 0.82 | DPP4 (0.49) | MMP12DPP4TSHRCTSGCTRB1 | |
| SCHEMBL7284686 | 0.82 | DPP4 (0.49) | MMP12DPP4TSHRCTSGCTRB1 | |
| Hydrochloric Acid SCHEMBL27562896 | 0.82 | MMP12 (0.54) | MMP12MMP13MMP2MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | WENZHOU UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | WENZHOU UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| CN-109734600-B | Synthesis method of chiral beta-hydroxy acid ester compound | 温州大学 | 2020-09-15 | — | — | CN | disclosed |
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | WENZHOU UNIVERSITY (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | WENZHOU UNIVERSITY (CN) | 2020-06-18 | — | — | US | disclosed |
| CN-109734600-A | A kind of synthetic method of chiral beta carboxylic acid ester type compound | 温州大学 | 2019-05-10 | — | — | CN | disclosed |
| EP-1113033-B1 | Polyhydroxyalkanoate | CANON KK (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1188782-B1 | Polyhydroxyalkanoate and manufacturing method thereof | CANON KK (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-7169598-B2 | Polyhydroxyalkanoate, method for production thereof and microorganisms for use in the same | CANON KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| CN-1870955-A | Kavalactone compositions and methods of use | KAVA PHARMACEUTICALS INC (US) | 2006-11-29 | — | — | CN | disclosed |
| US-20030060633-A1 | Asymmetric synthesis of kavalactones | SYNTA PHARMACEUTICALS CORP. | 2003-03-27 | — | — | US | disclosed |
| WO-2003013542-A1 | ASYMMETRIC SYNTHESIS OF KAVALACTONES | KAVA PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20020192241-A1 | Methods of using kavalactone compositions | SYNTA PHARMACEUTICALS CORP. | 2002-12-19 | — | — | US | disclosed |
| US-20020187169-A1 | Kavalactone compositions | SYNTA PHARMACEUTICALS CORP. | 2002-12-12 | — | — | US | disclosed |
| WO-2002091966-A1 | KAVALACTONE COMPOSITIONS AND METHODS OF USE | KAVA PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020160467-A1 | Polyhydroxyalkanoate and manufacturing method thereof | CANON KABUSHIKI KAISHA (JP) | 2002-10-31 | — | — | US | disclosed |
| EP-1188782-A2 | Polyhydroxyalkanoate and manufacturing method thereof | CANON KABUSHIKI KAISHA (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-20020022253-A1 | Polyhydroxyalkanoate, method for production thereof and microorganisms for use in the same | CANON KABUSHIKI KAISHA (JP) | 2002-02-21 | — | — | US | disclosed |
| CN-1321695-A | Poly(hydroxy alkanoate), its preparation method and use of microbe in its preparation | CANON KK (JP) | 2001-11-14 | — | — | CN | disclosed |
| EP-1113033-A2 | Polyhydroxyalkanoate, method for production thereof and microorganisms for use in the same | CANON KABUSHIKI KAISHA (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190013-A1 | METHOD FOR SYNTHESIZING CHIRAL BETA-HYDROXY ACID ESTER COMPOUND | HSD11B1, HACL2, HAAO | MMP12 1163/4885MMP13 1760/4885MMP2 1610/4885 |
| US-20020187169-A1 | Kavalactone compositions | KLK14, KLHL20, KLHL6 | MMP12 1285/4885MMP13 2485/4885MMP2 2322/4885 |
| US-10906860-B2 | Method for synthesizing chiral beta-hydroxy acid ester compound | HSD11B1, HACL2, HAAO | MMP12 1163/4885MMP13 1760/4885MMP2 1610/4885 |
| US-20020192241-A1 | Methods of using kavalactone compositions | KHK, KLK4, KLK14 | MMP12 2053/4885MMP13 2088/4885MMP2 1834/4885 |
| US-20030060633-A1 | Asymmetric synthesis of kavalactones | GNE, KLK14, ALG8 | MMP12 4104/4885MMP13 4312/4885MMP2 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.